first in human characterization of pi-2620, a ... 2017 _pi2620_seibyl...•pi-2620 binds to both tau...
TRANSCRIPT
0 50 100 150 2000
2
4
6
Time (min)
SUV
(g/m
L)
HCsubjects:SUVand SUVrHC0551yrs,MMSE29
0 50 100 150 2000
1
2
3
Time (min)
SUVr
(cer
ebel
lar c
orte
x)
0 50 100 150 2000
2
4
6
Time (min)
SUV
(g/m
L)
HC0853yrs,MMSE29
0 50 100 150 2000
1
2
3
Time (min)
SUVr
(cer
ebel
lar c
orte
x)
OlivierBarret1,JohnSeibyl1,AndrewStephens2,JenniferMadonia1,DavidAlagille1,AndreMueller2,MathiasBerndt2,HeikoKroth3,AndreasMuhs3,AndreaPfeifer3,GillesTamagnan1,Ludger Dinkelborg2,KennethMarek1,1Molecular
Neuroimaging,NewHaven,USA, 2Piramal Imaging,Berlin,Germany, 3 ACImmune,SA,Lausanne,Switzerland
STUDY DESIGN
RESULTS
CONCLUSIONS
BACKGROUND / RATIONALE RESULTS
• Positronemissiontomographymayproveausefultoolfordetectingthepresenceandspatialextentofbraintauaccumulation,akeypathologicfeatureofAlzheimer’sdisease(AD)andothernon-ADtauopathies.Currenttautracerssufferfromsub-optimalkineticsandhighoff-targetbinding,confoundingquantification,aswellasvariableaffinityfortauisoforms,diminishingutilityforevaluatingnon-ADtauopathies likeprogressivesupranuclear palsy(PSP).
• ThenovelPETtautracerPI-2620hasanIC50of1.8nM fortauinADbrainhomogenatecompetition-assaysandbindsspecificallytotaudepositsonADbrainsections(Braak I-VI),Pick’sandPSPpathology.
• PI-2620bindstobothTauisoforms3Rand4Randdemonstrateshighselectivityoverbeta-amyloid,MAOAandMAOB,withverylowoff-targetbinding.
• Invivopreclinicalstudiesshowhighbrainuptakeandfastwash-outinmiceandnon-humanprimate.
Objective:ToextendthesestudiestofirstinhumanevaluationofthetauPETtracerPI-2620(MNI-960)inresearchparticipantswithandwithoutsuspectedtaupathology.
• Inanongoingclinicalstudy,participantsdiagnosedwithmildAlzheimer’s(AD),non-ADtauopathies,andhealthycontrols(HC)underwentdynamicPETimagingforapproximately3hfollowing350MBq bolusinjectionof18F-PI-2620.ADsubjectsandcontrolshadscreeningflorbetaben PETscreeningscanstoconfirmcohort- appropriateamyloidstatus
• Venousbloodwasobtainedtocharacterizethemetabolismofparentcompound.• SUVandSUVrs werecalculatedforbrainregionsderivedfromtheHammerstemplateplacedon
eachspatiallynormalized,greymattersegmentedPETimagevolume.• Inaddition,asinglehumanbiodistribution/dosimetrystudywasperformedinamalecontrolwith
preliminaryestimatesoftargetorganradiationabsorbeddoseandEffectiveDose(ED).
Table1.BaselineCharacteristics
Fig.2aPETintwohealthycontrolsacquired60-90minpostinjectionof350MBq of18F-PI-2620.Notelackofnon-specific,off-targetuptake.SUVtime-activitycurvesshowhighbrainpenetranceandfastwash-outwithsecularequilibriumachievedat50minandpersistingforthenext1.5hinAD,PSP,andcontrols(Fig.2b,c).
• InitialclinicaldatainADsubjectsshowsrobustbrainuptakeandfastwash-outinnon-targetregions.
• Noincreaseduptakewasnotedinchoroidplexus,striatum,amygdala,orotherregionsseeninfirstgenerationtauagents.
• SUVr timecurvessuggestaplateauoccurs60-90minpostinjectionwithresultantSUVrsinabnormalregionsupto2.5-2.8.
• Blooddataconfirmedfastkineticswith20%ofparentcompoundpresentat60min.• Nolipophilicmetaboliteswereobserved.• ADandPSPsubjectsshowexpectedpatternsoftauuptake.• Non-invasivepk modelingindicatesSUVr (60-90min)couldbeagoodproxyforBPnd
pendingfullvalidationofquantitativeoutcomemeasuresusingmetabolitecorrectedarterialinputfunctions.
0.0
SUVr
6.0
Substantianigra
60-90min75yrs,MMSE19,PSPscale 54
Pallidum
0.0
SUVr
5.0
HC05
HC08
60-90minp.i.
SUVR-1andBPND CorrelationinADSubjects
0.0
SUV(g/m
l)
Subject03-01-02(male)
10.0
0-10 66-87 164-210 276-322
min
12mmsmoothingapplied
R L
22-43
Fig.1.Healthycontrolbiodistribution anddosimetry
1. Eliminationisviabothhepatobiliary(mainroute)andurinarypathways.
2. Targetorganswithhighestexposurearegallbladderwallandupperlargeintestine.
3. TheEffectiveDoseper185MBq(5mCi)injectionis4.1mSvwithnoUBvoiding,and4.0mSvwith2hourUBvoidingintervalforadultmale,whichcomparesfavorablytoother18Fradiopharmaceuticals.
Fig.2b,c PETinfourAD(above)andtwoPSP(below)participantsacquired60-90minpostinjectionof350MBq of18F-PI-2620.ThreeoftheADpatientsshowtypicalasymmetricpatternsoftraceruptakeinvolvingtemporallobes,precuneus,andpostcingulate.ThethirdADsubject,verymildclinically,showsnouptake,aphenomenanotedwithAV1451(Pontecorvo,etal,Brain,Jan11,2017).ThePSPsubjects(below)showfocallydiscreteuptakeinsubstantia nigra andpallidum,consistentwithpathologicalreportsintheliterature.
Fig.3PETSUVr forleftcorticalandsubcorticalbrainregionsshowgoodseparationbetweenvisuallydetectedareasofhigheruptakedescribedabove(Fig2)andelevatedSUVrs.
Fig.4CorrelationofSUVrs andBPnddeterminedbynon-invasivePKmodelingsuggests60-90minsmaybestalignwithBPnd.
Fig.5MetabolismofPI-2620shows,similarlyacrosssubjects,rapidkineticswith20%ofparentpresentat60minute(top)andproductionofhydrophilicmetabolites(bottom).Thelatterareunlikelytocrosstheblood-brainbarrier.
#224
Table2.SUVr Measures
ADsubjects:SUVand SUVr
0 50 100 150 2000
2
4
6
Time (min)
SUV
(g/m
L)
PSPsubjects:SUVand SUVr
PSP03
0 50 100 150 2000
1
2
3
Time (min)
SU
Vr (c
ereb
ella
r co
rtex
)
0 50 100 150 2000
2
4
6
Time (min)
SUV
(g/m
L)
PSP07
FL_OFC_L
FL_OFC_RTL_SupLat_L
TL_SupLat_R
TL_InfLat_L
TL_InfLat_R
TL_Mesial_L
TL_Mesial_R
PL_L
PL_R
OL_L
OL_R
Cing_Ant_L
Cing_Ant_R
Cing_Post_L
Cing_Post_R
CaudateNucl_LCaudateNucl_RPutamen_LPutamen_RCerebellumPallidum_LPallidum_RS_nigra_LS_nigra_R
0 50 100 150 2000
1
2
3
Time (min)
SU
Vr (c
ereb
ella
r co
rtex
)
0 50 100 150 2000
2
4
6
Time (min)
SU
V (
g/m
L)
0 50 100 150 2000
2
4
6
Time (min)
SU
V (
g/m
L)
0 50 100 150 2000
2
4
6
Time (min)
SU
V (
g/m
L)
0 50 100 150 2000
1
2
3
Time (min)
SU
Vr
(cere
bellar
co
rtex)
0 50 100 150 2000
1
2
3
Time (min)
SU
Vr
(cere
bellar
co
rtex)
0 50 100 150 2000
1
2
3
Time (min)
SU
Vr
(cere
bellar
co
rtex)
ADsubject01
MMSE7
ADsubject02
MMSE22
ADsubject04
MMSE26
Cing_Ant_L
Cing_Ant_R
CaudateNucl_L
CaudateNucl_R
Putamen_L
Putamen_R
Pallidum_L
Pallidum_R
S_nigra_L
S_nigra_R
FL_OFC_L
FL_OFC_R
TL_SupLat_L
TL_SupLat_R
TL_InfLat_L
TL_InfLat_R
TL_Mesial_LTL_Mesial_R
PL_LPL_R
OL_LOL_R
Cing_Post_L
Cing_Post_R
Cerebellum
0 50 100 1500
1
2
3
Time (min)
SU
Vr
(cere
bellar
co
rtex)
0 50 100 1500
2
4
6
Time (min)
SU
V (
g/m
L)
ADsubject09
MMSE17
0.0
SUVr
5.0
AD01MMSE7
AD02MMSE22
AD04MMSE26
60-90minp.i.
AD09MMSE17
HC05
HC08
PSP03
PSP07
AD01
AD04
AD02
AD09
FL_OFC_L 1.21 1.30 1.27 1.32 1.60 1.03 1.40 1.50FL_OFC_R 1.19 1.30 1.30 1.37 1.31 1.05 1.33 1.49TL_SupLat_L 1.07 1.03 1.15 1.30 2.01 1.06 2.00 1.36TL_SupLat_R 1.17 1.01 1.17 1.27 1.61 1.08 1.46 1.81TL_InfLat_L 1.06 1.09 1.27 1.23 2.27 1.15 2.27 1.77TL_InfLat_R 1.12 1.07 1.17 1.19 1.70 1.15 1.57 2.10TL_Mesial_L 1.07 1.04 1.27 1.25 1.70 1.15 1.85 1.71TL_Mesial_R 1.20 1.15 1.22 1.34 1.40 1.27 1.23 2.16PL_L 1.07 1.03 1.04 1.25 1.69 0.95 1.53 1.06PL_R 1.11 0.98 1.04 1.20 1.55 0.94 1.21 1.13OL_L 1.17 1.12 1.19 1.38 2.04 1.04 1.36 1.23OL_R 1.22 1.11 1.22 1.41 1.65 1.10 1.29 1.50Cing_Ant_L 0.96 0.88 0.97 1.08 1.05 0.75 1.17 0.89Cing_Ant_R 1.00 0.84 0.85 1.05 0.91 0.88 1.04 0.90Cing_Post_L 0.99 0.88 1.05 1.15 1.64 0.86 1.39 1.07Cing_Post_R 0.95 0.86 0.99 1.17 1.63 0.86 1.26 1.14CaudateNucl_L 0.85 0.64 0.89 0.96 0.88 0.66 0.85 0.67CaudateNucl_R 0.88 0.67 0.85 1.05 0.93 0.54 0.97 0.64Putamen_L 0.93 0.84 1.42 1.19 1.11 0.88 1.32 1.01Putamen_R 1.07 0.73 1.26 1.37 0.92 0.87 1.12 1.03Pallidum_L 1.09 0.83 2.11 1.59 1.12 0.97 1.19 0.96Pallidum_R 1.07 0.74 1.99 1.85 0.94 0.84 1.26 1.00S_nigra_L 1.68 1.15 2.58 2.03 1.16 1.21 1.57 1.54S_nigra_R 1.54 1.05 2.41 1.70 1.04 1.39 1.60 1.08
FL_OFC
TL_SupLat
TL_InfLat
TL_Mes
ial PL OL
Cing_Ant
Cing_Post
0
1
2
3
Left Cortical VOIs
SUVr
(cer
ebel
lar c
orte
x)
AD Subject 1
PSP Subject 3
HC Subject 5
AD Subject 4
AD Subject 2
PSP Subject 7
HC Subject 8
AD Subject 9
Caudate
Nucl
Putamen
Pallidum
S_nigra
0
1
2
3
Left Subcortical VOIs
SUVr
(cer
ebel
lar c
orte
x)
0 20 40 60 800
20
40
60
80
100
Percent Unchanged Parent
Time (min)
% P
aren
t fra
ctio
n
AD Subject 1
PSP Subject 3
HC Subject 5
AD Subject 4
AD Subject 2
HC Subject 8
PSP Subject 7
AD Subject 9
0 20 40 60 800.0
0.5
1.0
1.5
Total Plasma
Time (min)
SUV
(g/m
L)
AD Subject 1
PSP Subject 3
HC Subject 5
AD Subject 4
AD Subject 2
HC Subject 8
PSP Subject 7
AD Subject 9
FIRSTINHUMANCHARACTERIZATIONOFPI-2620,ANEXTGENERATIONPETTRACERFORASSESSINGTAUINALZHEIMER’SDISEASEANDOTHERTAUOPATHIES
Subject number Cohort Age MMSE CDR ADAS-Cog PSPScale Injecteddose(MBq)
MNI-960-01-01-01 AD01 63 7 2 53 N/A 340.4
MNI-960-01-01-02 AD02 70 22 0.5 21 N/A 351.5
MNI-960-01-01-03 PSP03 75 19 N/A N/A 54 358.9
MNI-960-01-01-04 AD04 65 26 0.5 11 N/A 340.4
MNI-960-01-01-05 HC05 51 29 0 6 N/A 347.8
MNI-960-01-01-07 PSP07 66 26 N/A N/A 38 351.5
MNI-960-01-01-08 HC08 53 29 0 5 N/A 355.2
MNI-960-01-01-09 AD09 80 17 0.5 14 N/A 351.5